Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Non-Rx chlamydia drug

This article was originally published in The Tan Sheet

Executive Summary

U.K. consumers will be able to obtain an oral antibiotic for the treatment of chlamydia without a prescription, the Medicines and Healthcare products Regulatory Agency announces Aug. 6. Actavis' Clamelle (azithromycin) will be available to consumers 16 years old and up if they test positive for the infection and have no symptoms, as well as for their sexual partners, MHRA says. Actavis is developing training materials and a formal launch plan for Clamelle's switch from prescription only to pharmacy status, which is similar to behind-the-counter in the U.S. In March, MHRA approved urinary tract infection drug Cystobid 100 mg (nitrofurantoin) - Procter & Gamble's Macrobid in the U.S. - for pharmacy sale in a move consistent with the agency's plan to move more POM products into the P class to reduce health care costs, promote self-care and expand the role of pharmacists in treatment (1"The Tan Sheet" March 10, 2008, In Brief and 2"The Tan Sheet" June 6, 2005, p. 4)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel